1. Home
  2. NOTV vs ELTX Comparison

NOTV vs ELTX Comparison

Compare NOTV & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOTV
  • ELTX
  • Stock Information
  • Founded
  • NOTV 1974
  • ELTX 2011
  • Country
  • NOTV United States
  • ELTX United States
  • Employees
  • NOTV N/A
  • ELTX N/A
  • Industry
  • NOTV Biotechnology: Pharmaceutical Preparations
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NOTV Health Care
  • ELTX Health Care
  • Exchange
  • NOTV Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • NOTV 137.5M
  • ELTX 121.7M
  • IPO Year
  • NOTV 1997
  • ELTX N/A
  • Fundamental
  • Price
  • NOTV $2.21
  • ELTX $6.30
  • Analyst Decision
  • NOTV Strong Buy
  • ELTX Strong Buy
  • Analyst Count
  • NOTV 3
  • ELTX 3
  • Target Price
  • NOTV $5.92
  • ELTX $9.50
  • AVG Volume (30 Days)
  • NOTV 552.5K
  • ELTX 36.3K
  • Earning Date
  • NOTV 05-09-2025
  • ELTX 03-31-2025
  • Dividend Yield
  • NOTV N/A
  • ELTX N/A
  • EPS Growth
  • NOTV N/A
  • ELTX N/A
  • EPS
  • NOTV N/A
  • ELTX N/A
  • Revenue
  • NOTV $475,114,000.00
  • ELTX N/A
  • Revenue This Year
  • NOTV $6.37
  • ELTX N/A
  • Revenue Next Year
  • NOTV $5.74
  • ELTX N/A
  • P/E Ratio
  • NOTV N/A
  • ELTX N/A
  • Revenue Growth
  • NOTV N/A
  • ELTX N/A
  • 52 Week Low
  • NOTV $1.23
  • ELTX $3.34
  • 52 Week High
  • NOTV $11.20
  • ELTX $11.45
  • Technical
  • Relative Strength Index (RSI)
  • NOTV 35.56
  • ELTX 31.74
  • Support Level
  • NOTV $2.72
  • ELTX $7.54
  • Resistance Level
  • NOTV $3.35
  • ELTX $8.13
  • Average True Range (ATR)
  • NOTV 0.31
  • ELTX 0.46
  • MACD
  • NOTV -0.03
  • ELTX -0.13
  • Stochastic Oscillator
  • NOTV 16.79
  • ELTX 1.61

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: